Share on StockTwits

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) CMO Jeffrey K. Tobias sold 1,000 shares of the stock on the open market in a transaction dated Friday, May 16th. The shares were sold at an average price of $128.01, for a total transaction of $128,010.00. Following the completion of the transaction, the chief marketing officer now directly owns 47,103 shares in the company, valued at approximately $6,029,655. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

JAZZ has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, May 13th. They now have a $137.00 price target on the stock. Separately, analysts at TheStreet downgraded shares of Jazz Pharmaceuticals plc – to a “hold” rating in a research note on Monday, May 12th. Finally, analysts at R. F. Lafferty cut their price target on shares of Jazz Pharmaceuticals plc – from $140.00 to $130.00 in a research note on Friday, May 9th. They now have a “neutral” rating on the stock. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $165.63.

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 2.22% during mid-day trading on Tuesday, hitting $128.51. 750,261 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a one year low of $58.32 and a one year high of $176.60. The stock’s 50-day moving average is $134.3 and its 200-day moving average is $134.8. The company has a market cap of $7.632 billion and a price-to-earnings ratio of 99.95.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Thursday, May 8th. The company reported $1.61 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter last year, the company posted $1.37 earnings per share. Jazz Pharmaceuticals plc -’s revenue was up 25.8% compared to the same quarter last year. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.08 earnings per share for the current fiscal year.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.